Curanex Pharmaceuticals prices IPO of 3.75M shares at $4.00/share, gross $15M

Curanex Pharmaceuticals Inc

Gross proceeds $15M from 3.75M shares at $4.00/share; net proceeds ~$12.1M after underwriting discounts and expenses.
Shares expected to begin trading on Nasdaq (CURX) on Aug 26, 2025; close expected Aug 27, 2025.
Underwriters have 45-day option to purchase up to 562,500 additional shares to cover over-allotments.
Proceeds to fund Phyto-N (ulcerative colitis) development, GLP toxicology/pharmacokinetic studies, IND submission, and working capital.
Lead underwriter: Dominari Securities; co-underwriters: Pacific Century Securities and Revere Securities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.